Abstract:Paclitaxel (PTX) is a first-line chemotherapeutic agent to treat prostate cancer (PCa), but a large number of patients acquired drug resistance after short-term treatment. To develop combinational therapeutics to overcome PTX-resistant PCa, we established PTX-resistant LNCaP (LNCaP/PTX) cells and found that the LNCaP/PTX cells exhibited epithelial–mesenchymal transition (EMT) and enhanced metastasis during the selection process. We revealed that β-tubulin III, androgen receptor, and CXCR4 expressions were significantly increased in LNCaP/PTX cells and directly contributed to PTX resistance and EMT. Therefore, we developed prostate-specific membrane antigen aptamer (Apt)-functionalized shell–core nanoparticles (PTX/siRNAs NPs-Apt); the hydrophobic DSPE encapsulating PTX formed the dense inner core and the hydrophilic Apt-PEG2K with calcium phosphate (CaP) absorbing siRNAs formed the outer shell to sequentially release siRNAs and PTX, where CaP could trigger lysosomal escape to ensure that pooled siRNAs efficiently released into the cytoplasm to reverse EMT and resensitize PTX, while the PTX located in the core was subsequently released to exert the killing effect of chemotherapy to achieve the best synergistic effect. PTX/siRNAs NPs-Apt showed an enhanced tumor-targeting ability and achieved superior efficacy in the subcutaneous and orthotopic PCa tumor model with minimal side effects.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c00852?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c00852</a>.Expression level of P-gP and β-tubulin III in LNCaP and LNCaP/PTX cells detected by western blot; LNCaP/PTX cells was co-cultured with PBS, DHT, SDF-1α, or DHT + SDF-1α for 72 h for transwell assay and clone formation assay; infrared characterization spectra of DSPE-PEG2K-COOH and DSPE-PEG2K-Apt; cell viability of mouse fibroblast L929 cells and LNCaP/PTX cells with the treatment of various concentrations of blank Apt-NPs for 24, 48 ,and 72 h; investigation of shell–core nanoparticles in the LNCaP/PTX cell cycle-blocking ability by flow cytometry and apoptosis of LNCaP/PTX cells and different components after 72 h incubation; wound healing assay and invasion assay examined the cell migration ability after 72 h of incubation; pharmacokinetics of siRNAs and PTX; tumor inhibition rate in different groups; tumor sections were stained with Ki-67 and Bcl-2; body weight curves of tumor-bearing mice under different treatments; indices of hepatic functions after the final injection of different drug formulations in nude mice; histopathology of major organs after the final injection of different drug formulations in nude mice; small animal magnetic resonance imaging system and small animal ultrasound imaging system monitor mouse orthotopic prostate tumor size and tumor inhibition rate in different groups; tumor and lymph node metastases in different groups of mice three days after the last dose and normal intestinal tissue and mesenteric lymph node metastases; prostate and seminal vesicle location in Balb/c nude male mice (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c00852/suppl_file/am1c00852_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy

Polydopamine-Functionalized CA-(PCL-ran-PLA) Nanoparticles for Target Delivery of Docetaxel and Chemo-photothermal Therapy of Breast Cancer.

Aptamer‐conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer

In vitro study of a new theranostic smart niosomal nanostructure for direct delivery of docetaxel via anti-PSMA aptamer

Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer

An effective strategy for development of docetaxel encapsulated gold nanoformulations for treatment of prostate cancer

Enhanced Antitumor Efficacy, Biodistribution and Penetration of Docetaxel-Loaded Biodegradable Nanoparticles.

Sequential Release of Pooled siRNAs and Paclitaxel by Aptamer-Functionalized Shell–Core Nanoparticles to Overcome Paclitaxel Resistance of Prostate Cancer

Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer

Study on the Prostate Cancer-Targeting Mechanism of Aptamer-Modified Nanoparticles and Their Potential Anticancer Effect in Vivo.

Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles

Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer

Au/Doc/Quer@PDA/A10-3.2 Nanoparticles for targeted treatment of docetaxel-resistant prostate cancer

Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer

Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model

Development of Novel Paclitaxel-Loaded ZIF-8 Metal-Organic Framework Nanoparticles Modified with Peptide Dimers and an Evaluation of Its Inhibitory Effect against Prostate Cancer Cells

Co-delivery of docetaxel and bortezomib based on a targeting nanoplatform for enhancing cancer chemotherapy effects.

Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer